Triple negative scores a positive with pembro.

With recent reporting of improved event-free survival in KEYNOTE 522, ASCO is now officially recommending neoadjuvant and adjuvant pembrolizumab for all eligible stage II-III triple negative breast cancer patients. It can be delivered either every 3 weeks at 200 mg or every 6 weeks at 400 mg. In a unique acknowledgement of radiation as a common part of the treatment algorithm, it is specified that the adjuvant pembro can be started either concurrently with radiation or after completion of radiation. | Korde, J Clin Oncol 2022